ArticleFrontiers in dementia2023
Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women.
Article in Frontiers in dementia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- The extragonadal biology of gonadotropin hormones: should we rename these?Endocrine connections · 2026Article
- Sex differences in brain glucose metabolism in alzheimer's disease: A voxel-based study.GeroScience · 2026Article
- Premenopausal bilateral oophorectomy leads to steeper declines in gray matter volume and alterations in perfusion and brain bioenergetics.Scientific reports · 2026Article
- Women's midlife: the front line of Alzheimer prevention.The Journal of clinical investigation · 2026Review
- Gonadotropins Across the Lifespan: Their role in the Neurodevelopment-Neurodegeneration Continuum.The Yale journal of biology and medicine · 2026Review
- Mechanistic redundancy and hierarchy of aging mechanisms: implications for strategies to extend healthspan and biomarker integration.Frontiers in aging · 2026Review
- APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review.The journal of prevention of Alzheimer's disease · 2025Article
- Targeting FSH for osteoporosis, obesity, and Alzheimer's disease.Trends in molecular medicine · 2025Review
- The Hypothalamic-Pituitary-Ovarian Axis, Ovarian Disorders, and Brain Aging.Endocrinology · 2025Review
- Dural ectopic lymphatic structures accumulate during aging and exhibit dysregulation in neurodegenerative diseases.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The interplay between age at menopause and synaptic integrity on Alzheimer's disease risk in women.Science advances · 2025Article
- Elevated gonadotropins and risk of dementia in Chinese adults aged over 80: a cross-sectional study.Frontiers in aging neuroscience · 2025Article
- Article
- Follicle-stimulating hormone linked to cognitive decline and amyloid burden in postmenopausal women.Frontiers in aging neuroscience · 2025Article
- Causal association of sex hormone-related traits with Alzheimer's disease: a multivariable and network Mendelian randomization analysis.Frontiers in neurology · 2025Article
- Neuroendocrinology of bone.Pituitary · 2024Review
- TransgenicPharmaceuticals (Basel, Switzerland) · 2024Article
- Gene-Dose-Dependent Reduction Fshr Expression Improves Spatial Memory Deficits in Alzheimer's Mice.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Introduction: In preclinical studies, menopausal elevations in pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), trigger Alzheimer's disease (AD) pathology and synaptic loss in female animals. Herein, we took a translational approach to test whether gonadotropin elevations are linked to AD pathophysiology in women. Methods: We examined 191 women ages 40-65 years, carrying risk factors for late-onset AD, including 45 premenopausal, 67 perimenopausal, and 79 postmenopausal participants with clinical, laboratory, cognitive exams, and volumetric MRI scans. Half of the cohort completed Results: FSH levels were positively associated with Aβ load in frontal cortex (multivariable adjusted Discussion: Increasing serum gonadotropin levels, especially FSH, are associated with higher Aβ load and lower GMV in some AD-vulnerable regions of midlife women at risk for AD. These findings are consistent with preclinical work and provide exploratory hormonal targets for precision medicine strategies for AD risk reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.